Aurinia Pharmaceuticals Inc (AUPH)

[Jesspro]

It would be naive to think that auph is not in the crosshairs of a few hedge funds in the likes of Denner and others. They have paid analysts crisscrossing the world to get intelligence to suit their purpose especially that
the window of opportunity is getting smaller and expensive by the months. Phase 3 will be over in less than a year with the expectation that the result will be equal or better than p2 given that the protocol of the p2 and p3 is the same with the p3 trial subjects receiving care in a better and suitable environments compare to p2 trial subjects.